TP53 and myelodysplastic syndrome: Furthermore, as previously discussed, allo-HSCT is the only curative option for t-MDS cases, regardless of the TP53 mutational status; the outcome of transplanted t-MDS is, in fact, similar to those of transplanted de novo MDS [113].